Home/Filings/4/0000899243-20-026193
4//SEC Filing

VV Manager II, LLC 4

Accession 0000899243-20-026193

CIK 0001818794other

Filed

Sep 22, 8:00 PM ET

Accepted

Sep 23, 7:11 PM ET

Size

20.3 KB

Accession

0000899243-20-026193

Insider Transaction Report

Form 4
Period: 2020-09-21
Transactions
  • Conversion

    Common Stock

    2020-09-21+2,087,1302,087,130 total(indirect: See footnotes)
  • Purchase

    Common Stock

    2020-09-21$19.00/sh+22,005$418,09579,921 total(indirect: See footnote)
  • Conversion

    Series B Preferred Stock

    2020-09-216,922,8030 total(indirect: See footnotes)
    Common Stock (2,087,130 underlying)
  • Purchase

    Common Stock

    2020-09-21$19.00/sh+792,995$15,066,9052,880,125 total(indirect: See footnotes)
  • Conversion

    Common Stock

    2020-09-21+57,91657,916 total(indirect: See footnote)
  • Conversion

    Series B Preferred Stock

    2020-09-21192,1020 total(indirect: See footnote)
    Common Stock (57,916 underlying)
Transactions
  • Conversion

    Common Stock

    2020-09-21+57,91657,916 total(indirect: See footnote)
  • Conversion

    Common Stock

    2020-09-21+2,087,1302,087,130 total(indirect: See footnotes)
  • Purchase

    Common Stock

    2020-09-21$19.00/sh+22,005$418,09579,921 total(indirect: See footnote)
  • Conversion

    Series B Preferred Stock

    2020-09-216,922,8030 total(indirect: See footnotes)
    Common Stock (2,087,130 underlying)
  • Conversion

    Series B Preferred Stock

    2020-09-21192,1020 total(indirect: See footnote)
    Common Stock (57,916 underlying)
  • Purchase

    Common Stock

    2020-09-21$19.00/sh+792,995$15,066,9052,880,125 total(indirect: See footnotes)
Transactions
  • Conversion

    Common Stock

    2020-09-21+2,087,1302,087,130 total(indirect: See footnotes)
  • Purchase

    Common Stock

    2020-09-21$19.00/sh+792,995$15,066,9052,880,125 total(indirect: See footnotes)
  • Conversion

    Common Stock

    2020-09-21+57,91657,916 total(indirect: See footnote)
  • Conversion

    Series B Preferred Stock

    2020-09-216,922,8030 total(indirect: See footnotes)
    Common Stock (2,087,130 underlying)
  • Conversion

    Series B Preferred Stock

    2020-09-21192,1020 total(indirect: See footnote)
    Common Stock (57,916 underlying)
  • Purchase

    Common Stock

    2020-09-21$19.00/sh+22,005$418,09579,921 total(indirect: See footnote)
Footnotes (4)
  • [F1]On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
  • [F2]The shares are held directly by Vida Ventures II, LLC ("Vida II"). VV Manager II, LLC ("VV Manager II") is the manager of Vida II. Arie Belldegrun, Fred Cohen, and Leonard Potter are the members of the management committee of VV Manager II (the "Management Committee") and Stefan Vitorovic, Arjun Goyal, Helen Kim, Rajul Jain, and Joshua Kazam are the members of the investment committee of VV Manager II (the "Investment Committee").
  • [F3](Continued from Footnote 2) Each of the Management Committee, the Investment Committee and the respective members thereof may be deemed to share voting and dispositive power over the shares held by Vida II. VV Manager II, the Management Committee, the Investment Committee and each member of each of the Management Committee and Investment Committee disclaims beneficial ownership over the securities held of record by Vida II and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein.
  • [F4]The shares are held directly by Vida Ventures II-A, LLC ("Vida II-A"). VV Manager II is the manager of Vida II-A. Each of the Management Committee ,the Investment Committee and the respective members thereof may be deemed to share voting and dispositive power over the shares held by Vida II-A. VV Manager II, the Management Committee, the Investment Committee and each member of each of the Management Committee and Investment Committee disclaims beneficial ownership over the securities held of record by Vida II-A and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein.

Issuer

Dyne Therapeutics, Inc.

CIK 0001818794

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001824569

Filing Metadata

Form type
4
Filed
Sep 22, 8:00 PM ET
Accepted
Sep 23, 7:11 PM ET
Size
20.3 KB